JP2022514799A5 - - Google Patents

Info

Publication number
JP2022514799A5
JP2022514799A5 JP2021543577A JP2021543577A JP2022514799A5 JP 2022514799 A5 JP2022514799 A5 JP 2022514799A5 JP 2021543577 A JP2021543577 A JP 2021543577A JP 2021543577 A JP2021543577 A JP 2021543577A JP 2022514799 A5 JP2022514799 A5 JP 2022514799A5
Authority
JP
Japan
Prior art keywords
compound
compound according
pharmaceutical composition
hydrogen
formula
Prior art date
Application number
JP2021543577A
Other languages
English (en)
Japanese (ja)
Other versions
JP7383030B2 (ja
JPWO2020074461A5 (https=
JP2022514799A (ja
Filing date
Publication date
Priority claimed from GBGB1816369.1A external-priority patent/GB201816369D0/en
Application filed filed Critical
Publication of JP2022514799A publication Critical patent/JP2022514799A/ja
Publication of JP2022514799A5 publication Critical patent/JP2022514799A5/ja
Publication of JPWO2020074461A5 publication Critical patent/JPWO2020074461A5/ja
Application granted granted Critical
Publication of JP7383030B2 publication Critical patent/JP7383030B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543577A 2018-10-08 2019-10-07 Tyk2キナーゼ阻害剤 Active JP7383030B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1816369.1A GB201816369D0 (en) 2018-10-08 2018-10-08 Pharmaceutical compounds
GB1816369.1 2018-10-08
PCT/EP2019/077118 WO2020074461A1 (en) 2018-10-08 2019-10-07 Tyk2 kinase inhibitors

Publications (4)

Publication Number Publication Date
JP2022514799A JP2022514799A (ja) 2022-02-15
JP2022514799A5 true JP2022514799A5 (https=) 2022-09-28
JPWO2020074461A5 JPWO2020074461A5 (https=) 2022-09-28
JP7383030B2 JP7383030B2 (ja) 2023-11-17

Family

ID=64397425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543577A Active JP7383030B2 (ja) 2018-10-08 2019-10-07 Tyk2キナーゼ阻害剤

Country Status (18)

Country Link
US (1) US12187716B2 (https=)
EP (1) EP3864009B1 (https=)
JP (1) JP7383030B2 (https=)
KR (1) KR102844196B1 (https=)
CN (1) CN113056456B (https=)
AU (1) AU2019359320B2 (https=)
BR (1) BR112021006424A2 (https=)
CA (1) CA3111049A1 (https=)
DK (1) DK3864009T3 (https=)
ES (1) ES3021420T3 (https=)
FI (1) FI3864009T3 (https=)
GB (1) GB201816369D0 (https=)
IL (1) IL281599B2 (https=)
MX (1) MX2021003929A (https=)
PL (1) PL3864009T3 (https=)
PT (1) PT3864009T (https=)
SG (1) SG11202102490TA (https=)
WO (1) WO2020074461A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005114D0 (en) * 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
JP2024539280A (ja) 2021-10-25 2024-10-28 カイメラ セラピューティクス, インコーポレイテッド Tyk2分解剤およびそれらの使用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
ATE394102T1 (de) 2000-06-28 2008-05-15 Astrazeneca Ab Substituierte chinazolin-derivate und deren verwendung als aurora-2-kinase inhibitoren
CN100400040C (zh) 2000-10-30 2008-07-09 詹森药业有限公司 三肽酶抑制剂
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
EP1684750B1 (en) 2003-10-23 2010-04-28 AB Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
KR20080066938A (ko) 2005-10-07 2008-07-17 깃세이 야쿠힌 고교 가부시키가이샤 질소 함유 복소환 화합물 및 그것을 함유하는 의약 조성물
ES2352320T3 (es) 2006-05-12 2011-02-17 Ab Science Nuevo procedimiento para la síntesis de compuestos de 2-aminoxazol.
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
ES2395581T3 (es) 2007-06-20 2013-02-13 Merck Sharp & Dohme Corp. Inhibidores de quinasas janus
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
WO2009155156A1 (en) 2008-06-18 2009-12-23 Merck & Co., Inc. Inhibitors of janus kinases
EP2310384B1 (en) 2008-07-09 2014-04-09 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
CA2793024A1 (en) 2010-03-17 2011-09-22 F. Hoffmann-La Roche Ag Imidazopyridine compounds, compositions and methods of use
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20140228349A1 (en) 2011-10-12 2014-08-14 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
KR101202026B1 (ko) 2012-07-03 2012-11-16 민호현 황토 석부작 제조 방법
MY194668A (en) 2012-11-08 2022-12-12 Bristol Myers Squibb Co Amide-substituted heterocyclic compounds useful as modulators of il-12, il-23 and/or ifn() responses
RU2652795C2 (ru) * 2013-09-03 2018-05-03 Сареум Лимитед Производные 2-фенил-оксазол-4-карбоксамида, модулирующие активность jak и tyk2 киназ
JP6310767B2 (ja) 2014-05-13 2018-04-11 日本電子株式会社 自動分析装置及びノズル洗浄方法
NO2721710T3 (https=) 2014-08-21 2018-03-31
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound

Similar Documents

Publication Publication Date Title
JP2013544887A5 (https=)
JP2020033360A5 (https=)
JP2017528507A5 (https=)
JP2018513107A5 (https=)
JP2014502641A5 (https=)
JP2017528503A5 (https=)
JP2012508734A5 (https=)
JP2018518537A5 (https=)
JP2015528471A5 (https=)
JP2021525729A5 (https=)
JP2012502017A5 (https=)
JP2015512406A5 (https=)
JP2020502047A5 (https=)
RU2017114352A (ru) АНТАГОНИСТЫ ИНТЕГРИНА ανβ6
JP2015500223A5 (https=)
JP2015505564A5 (https=)
JPWO2019160057A5 (https=)
JP2019516739A5 (https=)
JP2016510326A5 (https=)
JP2018537513A5 (https=)
JP2015510916A5 (https=)
JP2021535147A5 (https=)
PH12021550170A1 (en) Pharmaceutical dosage form which can be adminitered orally and has modified release
JP2022514799A5 (https=)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3